By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A US Food and Drug Administration panel will not review Gen-Probe's submission for clearance of its Progensa PCA3 assay for prostate cancer in October as previously scheduled, the San Diego-based company disclosed in a regulatory filing after the close of the market Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.